# Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

> **NCT06717815** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nanjing Immunophage Biotech Co., Ltd** · enrollment: 36 (estimated)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** IPG11406

## Key facts

- **NCT ID:** NCT06717815
- **Lead sponsor:** Nanjing Immunophage Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2026-04-22
- **Final completion:** 2026-04-22
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06717815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06717815, "Phase IIa Study for IPG11406 in Patients With Lupus Nephritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06717815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*